CN105445171A - 自然杀伤细胞脱颗粒的流式细胞术检测方法 - Google Patents
自然杀伤细胞脱颗粒的流式细胞术检测方法 Download PDFInfo
- Publication number
- CN105445171A CN105445171A CN201610013454.1A CN201610013454A CN105445171A CN 105445171 A CN105445171 A CN 105445171A CN 201610013454 A CN201610013454 A CN 201610013454A CN 105445171 A CN105445171 A CN 105445171A
- Authority
- CN
- China
- Prior art keywords
- cell
- natural killer
- detection method
- antibody
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 83
- 238000001514 detection method Methods 0.000 title claims abstract description 29
- 238000000684 flow cytometry Methods 0.000 title claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 124
- 230000000694 effects Effects 0.000 claims abstract description 15
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims abstract description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 4
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 4
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims abstract 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 21
- 238000005406 washing Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 11
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 9
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 9
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 9
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 231100000433 cytotoxic Toxicity 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000012447 hatching Effects 0.000 claims description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract description 3
- 230000002147 killing effect Effects 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000004907 flux Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract 1
- 239000012474 protein marker Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- MASKQITXHVYVFL-UHFFFAOYSA-N n,n-dimethyl-5-[[2-methyl-6-[(5-methylpyrazin-2-yl)carbamoyl]-1-benzofuran-4-yl]oxy]pyrimidine-2-carboxamide Chemical compound C1=NC(C(=O)N(C)C)=NC=C1OC1=CC(C(=O)NC=2N=CC(C)=NC=2)=CC2=C1C=C(C)O2 MASKQITXHVYVFL-UHFFFAOYSA-N 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
Landscapes
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610013454.1A CN105445171B (zh) | 2016-01-08 | 2016-01-08 | 自然杀伤细胞脱颗粒的流式细胞术检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610013454.1A CN105445171B (zh) | 2016-01-08 | 2016-01-08 | 自然杀伤细胞脱颗粒的流式细胞术检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105445171A true CN105445171A (zh) | 2016-03-30 |
CN105445171B CN105445171B (zh) | 2018-03-02 |
Family
ID=55555628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610013454.1A Active CN105445171B (zh) | 2016-01-08 | 2016-01-08 | 自然杀伤细胞脱颗粒的流式细胞术检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105445171B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110231275A (zh) * | 2019-05-20 | 2019-09-13 | 西安交通大学 | 一种基于流式细胞术检测nk细胞杀伤活性的方法 |
CN111527406A (zh) * | 2018-12-01 | 2020-08-11 | 铭道创新(北京)医疗技术有限公司 | 一种用于流式细胞仪分析的淋巴细胞样品的制备方法 |
CN112285083A (zh) * | 2020-10-28 | 2021-01-29 | 上海睿钰生物科技有限公司 | 一种细胞杀伤效力的评价方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1387046A (zh) * | 2001-05-22 | 2002-12-25 | 中国医学科学院基础医学研究所 | 检测外周血抗原特异性细胞毒性t淋巴细胞的方法及试剂盒 |
WO2005100553A2 (en) * | 2004-04-16 | 2005-10-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for assessment of cytotoxic lymphocyte activity |
CN101065669A (zh) * | 2004-01-23 | 2007-10-31 | 圣诺菲·帕斯图尔公司 | 细胞毒性测定法 |
-
2016
- 2016-01-08 CN CN201610013454.1A patent/CN105445171B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1387046A (zh) * | 2001-05-22 | 2002-12-25 | 中国医学科学院基础医学研究所 | 检测外周血抗原特异性细胞毒性t淋巴细胞的方法及试剂盒 |
CN101065669A (zh) * | 2004-01-23 | 2007-10-31 | 圣诺菲·帕斯图尔公司 | 细胞毒性测定法 |
WO2005100553A2 (en) * | 2004-04-16 | 2005-10-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for assessment of cytotoxic lymphocyte activity |
Non-Patent Citations (1)
Title |
---|
王晶: "CD107a表达对NK细胞与细胞毒性T细胞细胞毒功能缺陷性疾病筛查价值探讨", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111527406A (zh) * | 2018-12-01 | 2020-08-11 | 铭道创新(北京)医疗技术有限公司 | 一种用于流式细胞仪分析的淋巴细胞样品的制备方法 |
CN110231275A (zh) * | 2019-05-20 | 2019-09-13 | 西安交通大学 | 一种基于流式细胞术检测nk细胞杀伤活性的方法 |
CN110231275B (zh) * | 2019-05-20 | 2021-05-28 | 西安交通大学 | 一种基于流式细胞术检测nk细胞杀伤活性的方法 |
CN112285083A (zh) * | 2020-10-28 | 2021-01-29 | 上海睿钰生物科技有限公司 | 一种细胞杀伤效力的评价方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105445171B (zh) | 2018-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lim et al. | Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells | |
Bryceson et al. | Functional analysis of human NK cells by flow cytometry | |
Atibalentja et al. | Functional redundancy between thymic CD8α+ and Sirpα+ conventional dendritic cells in presentation of blood-derived lysozyme by MHC class II proteins | |
CN102471753B (zh) | 干细胞免疫调节应用方法和设备 | |
Oehler et al. | Natural cell‐mediated cytotoxicity in rats. I. Tissue and strain distribution, and demonstration of a membrane receptor for the Fc portion of IgG | |
CN104894065B (zh) | 一种nk细胞培养基及nk细胞的培养方法 | |
JPH11513490A (ja) | 生物学的活性ポリマー | |
CN105445171A (zh) | 自然杀伤细胞脱颗粒的流式细胞术检测方法 | |
Gan et al. | Mechanism of activation of human peripheral blood NK cells at the single cell level by Echinacea water soluble extracts: recruitment of lymphocyte–target conjugates and killer cells and activation of programming for lysis | |
Kehrl et al. | Human B cell activation and cell cycle progression: stimulation with anti‐μ and Staphylococcus aureus Cowan strain I | |
CN102741695A (zh) | 3d adcc nk facs测定法 | |
CN107904278B (zh) | 检测药物对细胞增殖影响的方法 | |
Obasanmi et al. | Peripheral blood mononuclear cells from patients with type 1 diabetes and diabetic retinopathy produce higher levels of IL-17A, IL-10 and IL-6 and lower levels of IFN-γ—A pilot study | |
CN105547971B (zh) | 细胞毒性t细胞脱颗粒的流式细胞术检测方法 | |
Schilling et al. | Requirement for non-T cells in the generation of cytotoxic T lymphocytes in vitro. I. Use of nude mice as source of non-T cells. | |
Lögaberg et al. | Role of the Ly 1 antigen in interleukin 1‐induced thymocyte activation | |
CN106950163A (zh) | 流式细胞术检测鸡胸腺t淋巴细胞亚群的方法 | |
Thomis et al. | The Jak family tyrosine kinase Jak3 is required for IL-2 synthesis by naive/resting CD4+ T cells | |
Matsumoto et al. | Fully closed cell sorter for immune cell therapy manufacturing | |
Andrews et al. | The limited immunocompetence of thymocytes within murine thymic nurse cells | |
CN106103701A (zh) | 改造的自然杀手细胞及其组成与用途 | |
CN106255886B (zh) | 检测活运动神经元蛋白质的表达的方法 | |
Kung et al. | Athymic nude CD4+ 8-T cells produce IL-2 but fail to proliferate in response to mitogenic stimuli. | |
CN104422763B (zh) | 抗原组在制备诊断疾病的试剂盒中的用途和试剂盒 | |
CN105200110B (zh) | 一种用于新药物开发的免疫毒性评价方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170810 Address after: 100000 No. 95, Yongan Road, Beijing, Xicheng District Applicant after: BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL University Address before: 100000 No. 95, Yongan Road, Beijing, Xicheng District Applicant before: Wang Zhao |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181129 Address after: 101109 Beijing Chaoyang District Beijing Shun Tung Street 6 hospital 26 Building 1 stories 101, 2 layer 201, 3 layer 301, 4 layer 401. Patentee after: BEIJING JINYU MEDICAL EXAMINATION LABORATORY Co.,Ltd. Address before: 100000 Yongan Road, Xicheng District, Beijing 95 Patentee before: BEIJING FRIENDSHIP HOSPITAL, CAPITAL MEDICAL University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191129 Address after: 510000 room 706, No. 10, helix 3 Road, international bio Island, Huangpu District, Guangzhou, Guangdong Province Patentee after: Guangzhou jinbilai Biotechnology Co.,Ltd. Address before: 101109 Beijing Chaoyang District Beijing Shun Tung Street 6 hospital 26 Building 1 stories 101, 2 layer 201, 3 layer 301, 4 layer 401. Patentee before: BEIJING JINYU MEDICAL EXAMINATION LABORATORY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200312 Address after: Room 406, room 101, floor 1, building 55, yard 5, Yujing East Road, Tongzhou District, Beijing 100000 Patentee after: BEIJING BEIKEWEI BIOLOTY TECHNOLOGY Co.,Ltd. Address before: 510000 room 706, No. 10, helix 3 Road, international bio Island, Huangpu District, Guangzhou, Guangdong Province Patentee before: Guangzhou jinbilai Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230605 Address after: 301700 room 106, building G6, Changyuan road international enterprise community, Wuqing Development Zone, Wuqing District, Tianjin Patentee after: Becoway (Tianjin) Biotechnology Co.,Ltd. Address before: Room 406, room 101, 1st floor, building 55, yard 5, Yujing East Road, Tongzhou District, Beijing Patentee before: BEIJING BEIKEWEI BIOLOTY TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |